Curcumin induces potent cytotoxic effects on myeloma cells independent of caspase activation

References

• Anand, P., et al., 2007. Bioavailability of curcumin: problems and promises. Molecular pharmaceutics, 4 (6), 807–818.
   PubMed Web of Science ®Google Scholar
• Bai, Q.-X. and Zhang, X.-Y., 2012. Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK. International journal of molecular sciences, 13 (4), 4831–4838.
   PubMed Web of Science ®Google Scholar
• Bharti, A.C., Donato, N., and Aggarwal, B.B., 2003. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. The journal of immunology, 171 (7), 3863–3871.
   PubMed Web of Science ®Google Scholar
• Bharti, A.C., et al., 2004. Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood, 103, 3175–3184.
   PubMed Web of Science ®Google Scholar
• Bolger, G.T., et al., 2019. Intense uptake of liposomal curcumin by multiple myeloma cell lines: comparison to normal lymphocytes, red blood cells and chronic lymphocytic leukemia cells. Anticancer research, 39, 1161–1168.
   PubMed Web of Science ®Google Scholar
• Canella, A., et al., 2016. The potential diagnostic power of extracellular vesicle analysis for multiple myeloma. Expert review of molecular diagnostics, 16 (3), 277–284.
   PubMed Web of Science ®Google Scholar
• Chaurasia, S., et al., 2015. Lipopolysaccharide based oral nanocarriers for the improvement of bioavailability and anticancer efficacy of curcumin. Carbohydrate polymers, 130, 9–17.
   PubMed Web of Science ®Google Scholar
• Di Marzo, L., et al., 2016. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget, 7, 60698.
   PubMed Web of Science ®Google Scholar
• Dimopoulos, M.A., et al., 2020. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood cancer journal, 10 (2), 1–19.
   PubMed Web of Science ®Google Scholar
• Fang, B.-M., et al., 2015. Curcumin enhances bortezomib treatment of myeloma by inhibiting heat shock protein 90 expression. Tropical journal of pharmaceutical research, 14 (2), 227–233.
   Web of Science ®Google Scholar
• Fotakis, G. and Timbrell, J.A., 2006. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicology letters, 160, 171–177.
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie, P., et al., 2015. Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer biology & therapy, 16 (1), 60–65.
   PubMed Web of Science ®Google Scholar
• Greil, R., et al., 2018. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer. Cancer chemotherapy and pharmacology, 82, 695–706.
   PubMed Web of Science ®Google Scholar
• Larsen, J., et al., 2013. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia, 27 (4), 941–946.
   PubMed Web of Science ®Google Scholar
• Liu, B., et al., 2007. Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line. Zhongguo shi yan xue ye xue za zhi, 15, 762–766.
   PubMedGoogle Scholar
• Liu, B., et al., 2008. Inhibitory effects of curcumin on human multiple myeloma cell lines and their mechanisms [J]. Tumor, 12, 1051–1054.
   Google Scholar
• Liu, Z., Smart, J.D., and Pannala, A.S., 2020. Recent developments in formulation design for improving oral bioavailability of curcumin: a review. Journal of drug delivery science and technology, 102082. doi:https://doi.org/10.1016/j.jddst.2020.102082
   Google Scholar
• Marinac, C.R., et al., 2020. Dissecting racial disparities in multiple myeloma. Blood cancer journal, 10 (2), 1–8.
   PubMed Web of Science ®Google Scholar
• Moloudizargari, M., et al., 2020. Targeting Hippo signaling pathway by phytochemicals in cancer therapy. Seminars in cancer biology. doi:https://doi.org/10.1016/j.semcancer.2020.05.005
   Google Scholar
• Park, J., et al., 2008. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Molecular oncology, 2 (4), 317–326.
   PubMed Web of Science ®Google Scholar
• Pohjala, L., et al., 2007. Assessing the data quality in predictive toxicology using a panel of cell lines and cytotoxicity assays. Analytical biochemistry, 362 (2), 221–228.
   PubMed Web of Science ®Google Scholar
• Ramakrishna, R., et al., 2020. Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy. Clinical case reports, 8 (4), 739–744.
   PubMed Web of Science ®Google Scholar
• Schinke, C., et al., 2020. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal, 10 (6), 1–9.
   PubMed Web of Science ®Google Scholar
• Shanbhag, V.K.L., 2017. Curcumin in chronic lymphocytic leukemia–a review. Asian pacific journal of tropical biomedicine, 7 (6), 505–512.
   Web of Science ®Google Scholar
• Shishodia, S., 2013. Molecular mechanisms of curcumin action: gene expression. Biofactors, 39, 37–55.
   PubMed Web of Science ®Google Scholar
• Tai, K., et al., 2019. Effect of β-sitosterol on the curcumin-loaded liposomes: Vesicle characteristics, physicochemical stability, in vitro release and bioavailability. Food chemistry, 293, 92–102.
   PubMed Web of Science ®Google Scholar
• Tofolean, I.T., et al., 2016. Cellular determinants involving mitochondrial dysfunction, oxidative stress and apoptosis correlate with the synergic cytotoxicity of epigallocatechin-3-gallate and menadione in human leukemia Jurkat T cells. Pharmacological research, 103, 300–317.
   PubMed Web of Science ®Google Scholar
• Viktoria, K., et al., 2020. Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models. Scientific reports (nature publisher group), 10. https://www.nature.com/articles/s41598-020-75499-3
   Google Scholar
• Wang, J., et al., 2015. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget, 6 (41), 43992–44004.
   PubMedGoogle Scholar
• Weidmann, E., et al., 1995. Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Annals of hematology, 70, 153–158.
   PubMed Web of Science ®Google Scholar
• Wong, R., et al., 2013. Curcumin enhances the cytotoxic and chemosensitising effects of lenalidomide in human multiple myeloma cells.
   Google Scholar
• Zaidi, A., Lai, M., and Cavenagh, J., 2017. Long-term stabilisation of myeloma with curcumin. Case reports, 2017, bcr2016218148.
   PubMedGoogle Scholar
• Zhang, Y., et al., 2019. Apoptosis of mouse myeloma cells induced by curcumin via the Notch3-p53 signaling axis. Oncology letters, 17, 127–134.
   PubMed Web of Science ®Google Scholar
• Zheng, C., et al., 2016. Synergistic effects of curcumin and bortezomib on multiple myeloma cells. International journal of clinical and experimental medicine, 9, 21787–21793.
   Web of Science ®Google Scholar